Bionime Corporation

Equities

4737

TW0004737002

Medical Equipment, Supplies & Distribution

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
68.8 ^TWD	-0.58%		-0.15%	-8.02%

Mar. 15	Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 14	Bionime Corporation Announces Dividend for the Year Ended December 31, 2023	CI

Bionime Corporation Announces Resignation of Marvin Wu as Globle Sales Division Officer

August 18, 2023 at 01:27 am EDT

Bionime Corporation announced Resignation of Marvin Wu as Globle Sales Division Officer. Name, title, and resume of the previous position holder: Marvin Wu /Special Assistant to hold a concurrent post. Effective date: August 18, 2023.

Latest news about Bionime Corporation

Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Bionime Corporation Announces Dividend for the Year Ended December 31, 2023	Mar. 14	CI
Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Bionime Corporation Announces TFDA Approval for iFree Continuous Glucose Monitoring System Second-Class Medical Device License	23-10-13	CI
Bionime Corporation Announces Resignation of Marvin Wu as Globle Sales Division Officer	23-08-18	CI
Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Bionime Corporation Announces Appointment of Aling Lai as New Member to the Remuneration Committee	23-08-09	CI
Bionime Corporation Appoints Aling Lai as Additional Member of Audit Committee	23-06-30	CI
Bionime Corporation Approves Cash Dividends, Payable on August 18, 2023	23-06-30	CI
Bionime Corporation Announces Election of Aling Lai as an Additional Independent Director	23-06-30	CI
Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Bionime Corporation Revises Cash Dividend for 2022	23-05-10	CI
Bionime Corporation Appoints Chen Hui-Zhen as Corporate Governance Officer	23-05-10	CI
Bionime Corporation Announces Cash Dividend for 2022	23-03-14	CI
Bionime Corporation Announces Resignation of Tai,Tsung-Kai as Institutional Director, Effective April 30, 2023	23-03-03	CI
Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Bionime Corporation Approves the Factory Area to Expand Building the Clean Room to Accommodate Production Equipment and Increase Production Capacity	22-11-09	CI
Bionime Corporation Got A Taiwan Clinical Study Report for Continuous Glucose Monitoring System	22-09-02	CI
Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI
Bionime Corporation Announces Members of the First Order Audit Committee of the Company	22-07-05	CI
Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI
Bionime Corporation Announces Cash Dividend for 2021	22-03-22	CI
Bionime Corporation Announces Replacement of the Representative of the Its Institutional Director	22-01-28	CI
Bionime Corporation Announce Demise of Lin,Ming-Hsiang, Institutional Director	22-01-10	CI

Chart Bionime Corporation

Duration

Period

More charts

Company Profile

Bionime Corporation is a Taiwan-based company principally engaged in the manufacture and distribution of blood glucose monitoring products. The Company's main products include blood glucose monitoring devices and blood glucose testing chips. Its products are applied in the testing and monitoring of blood glucose density. The Company distributes its products mainly to overseas markets, including Europe, Asia, the Americas and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

68.8 TWD

Average target price

80 TWD

Spread / Average Target

+16.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIONIME CORPORATION	-8.02%	129M
BIOMÉRIEUX	+0.89%	12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
DIASORIN S.P.A.	+1.78%	5.41B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
10X GENOMICS, INC.	-50.70%	3.29B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B

Diagnostic & Testing Substances